A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.

Timeline

Start: 2010-02
Primary completion: 2011-09
Completion: 2011-09

Publications

Background Doi T, Tamura K, Tanabe Y, Yonemori K, Yoshino T, Fuse N, Kodaira M, Bando H, Noguchi K, Shimamoto T, Ohtsu A. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Aug;76(2):409-16. doi: 10.1007/s00280-015-2810-z. Epub 2015 Jun 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-2206	Small molecule	45 mg	Oral
Subject	MK-2206	Small molecule	60 mg	Oral
Subject	MK-2206	Small molecule	135 mg	Oral
Subject	MK-2206	Small molecule	200 mg	Oral

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Summary

Timeline

Publications

Drugs

Indications